Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0M8EF
|
|||
Drug Name |
CD38 CAR-T Cell
|
|||
Drug Type |
CAR T Cell Therapy
|
|||
Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 1/2 | [1] | |
Company |
Chinese PLA General Hospital
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cyclic ADP-ribose hydrolase 1 (CD38) | Target Info | CAR-T-Cell-Therapy | [1] |
KEGG Pathway | Nicotinate and nicotinamide metabolism | |||
Metabolic pathways | ||||
Calcium signaling pathway | ||||
Hematopoietic cell lineage | ||||
Oxytocin signaling pathway | ||||
Salivary secretion | ||||
Pancreatic secretion | ||||
Epstein-Barr virus infection | ||||
NetPath Pathway | Leptin Signaling Pathway | |||
TCR Signaling Pathway | ||||
Panther Pathway | CCKR signaling map ST | |||
WikiPathways | Oxytocin signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.